KR101436644B1 - 당뇨병 치료제 - Google Patents

당뇨병 치료제 Download PDF

Info

Publication number
KR101436644B1
KR101436644B1 KR1020087011885A KR20087011885A KR101436644B1 KR 101436644 B1 KR101436644 B1 KR 101436644B1 KR 1020087011885 A KR1020087011885 A KR 1020087011885A KR 20087011885 A KR20087011885 A KR 20087011885A KR 101436644 B1 KR101436644 B1 KR 101436644B1
Authority
KR
South Korea
Prior art keywords
pitavastatin
enalapril
salt
diabetes
insulin resistance
Prior art date
Application number
KR1020087011885A
Other languages
English (en)
Korean (ko)
Other versions
KR20080091082A (ko
Inventor
다로 아오키
가츠토시 미요사와
Original Assignee
코와 가부시키가이샤
닛산 가가쿠 고교 가부시키 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코와 가부시키가이샤, 닛산 가가쿠 고교 가부시키 가이샤 filed Critical 코와 가부시키가이샤
Publication of KR20080091082A publication Critical patent/KR20080091082A/ko
Application granted granted Critical
Publication of KR101436644B1 publication Critical patent/KR101436644B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087011885A 2006-01-31 2007-01-30 당뇨병 치료제 KR101436644B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2006-00021817 2006-01-31
JP2006021817 2006-01-31
JP2006171250 2006-06-21
JPJP-P-2006-00171250 2006-06-21
PCT/JP2007/000041 WO2007088705A1 (fr) 2006-01-31 2007-01-30 Remede contre le diabete

Publications (2)

Publication Number Publication Date
KR20080091082A KR20080091082A (ko) 2008-10-09
KR101436644B1 true KR101436644B1 (ko) 2014-09-01

Family

ID=38327287

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087011885A KR101436644B1 (ko) 2006-01-31 2007-01-30 당뇨병 치료제

Country Status (3)

Country Link
JP (1) JP5101306B2 (fr)
KR (1) KR101436644B1 (fr)
WO (1) WO2007088705A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
KR102408951B1 (ko) * 2017-09-18 2022-06-13 삼성전자주식회사 글루코스 노출량 추정 장치 및 방법과, 글루코스 노출량 추정 모델 생성 장치 및 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020089433A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기화합물의 조합

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
WO2004080488A2 (fr) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020089433A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기화합물의 조합

Also Published As

Publication number Publication date
KR20080091082A (ko) 2008-10-09
JP5101306B2 (ja) 2012-12-19
WO2007088705A1 (fr) 2007-08-09
JPWO2007088705A1 (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
EP2141155B1 (fr) Agent prophylactique et/ou thérapeutique contre l'hyperlipidémie
EP1940364B1 (fr) Capsules de pirfenidone et excipients pharmacocompatibles
RU2560676C2 (ru) Противотуберкулезная композиция, содержащая соединения оксазола
CN112367986A (zh) 新脂质
JP5524196B2 (ja) 糖尿病を治療するための医薬組成物
KR101436644B1 (ko) 당뇨병 치료제
JP6860677B2 (ja) グローコカリキシンａ誘導体、その医薬的に許容できる塩または医薬組成物、およびこれらの乾癬治療用医薬の調製における使用
CA3044364A1 (fr) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione pour le traitement d'une steatose hepatique non alcoolique
EP2853261B1 (fr) Agent pour améliorer la dyssynergie vésico-urétrale
WO2006064826A1 (fr) COMPOSITION MEDICINALE CONTENANT UN INHIBITEUR DE LA FBPase
JP5105818B2 (ja) 医薬組成物
US8685952B2 (en) Method for the treatment of diabetes
WO2021047525A1 (fr) Sel d'un composé de benzothiopyrone, son procédé de préparation et son utilisation
RU2646475C2 (ru) Лечение диабета I и II типа
KR100759467B1 (ko) 차가버섯 또는 상황버섯으로부터 분리된 화합물을 함유하는통풍 예방 및 치료용 조성물
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
KR101503782B1 (ko) 신경 세포사 억제제
KR101381076B1 (ko) 트리글리세리드 저하제 및 고인슐린 혈증 개선제
WO2002092105A1 (fr) Composition renfermant de la s-adenosylmethionine destinee au traitement ou a la prevention du syndrome de resistance a l'insuline
CA2922013C (fr) Inducteurs chimiques d'hemoglobine foetale
JP6280050B2 (ja) 肥満症予防又は治療剤，リウマチの予防又は治療剤
AU2014240300B2 (en) Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients
WO2005117853A1 (fr) Agent thérapeutique pour l'hyperlipémie et agent thérapeutique pour le diabète
JP2006193516A (ja) ＦＢＰａｓｅ阻害剤を含有する医薬組成物
MXPA96002577A (en) Treatment of arterioesclerosis and xant

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
FPAY Annual fee payment

Payment date: 20180723

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20190724

Year of fee payment: 6